Welcome to Multibagg AI
Log in to access personalized features
IRIS
Multibagg AI is an AI powered stock research and analysis platform. We provide data, information, content, and analytics for publicly traded Indian companies listed on NSE and BSE. AI can make mistakes, check important information.
Research powered by GOALZEN CAPITAL SERVICES PRIVATE LIMITED · SEBI Research Analyst INH000013448
Prices might be delayed by a few minutes.
Join our Exclusive Community
Join our Exclusive Community
Made with 💙 in India. © Finsky Technologies Pvt Ltd. 2026
Get instant AI-powered insights about company performance, financials, and strategy. Ask questions about trends, competition, and developments while receiving responses backed by official documents and market data, with clear attribution to source documents.
Discovery themes featuring this stockBearish
4
Neutral
1
Bullish
9
Bearish
34
Neutral
1
Bullish
11
Bearish
30
Neutral
0
Bullish
2
Bearish
4
Neutral
1
Bullish
9
Bearish
4
Neutral
1
Bullish
9
Bearish
30
Neutral
0
Bullish
2
Bearish
30
Neutral
0
Bullish
2
Bearish
30
Neutral
0
Bullish
2
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
Discovery themes featuring this stock
Balaji Amines Limited is an integrated Indian speciality chemicals and amines manufacturer with multi‑location production in Maharashtra and Telangana, a 55% subsidiary Balaji Speciality Chemicals (BSCL), and a non‑core hospitality asset (Balaji Sarovar Premiere). The company produces core amines, derivatives, solvents and speciality chemistries and exports to over 50 countries while pursuing import substitution for regulated markets.
Q1 FY27 consolidated results showed robust operational improvement: revenue from operations at ₹456 crore (up ~25.7% YoY), EBITDA ₹121 crore (26% margin, up from 17% YoY) and PAT ₹78 crore (110% YoY). Margin expansion was a key feature, driven by higher utilisation, product mix improvements and lower relative other expenses during the quarter.
The company has advanced strategic capex: India’s first commercial 100,000 TPA Dimethyl Ether (DME) plant was commissioned in Q1 FY27, while N‑Methyl Morpholine (NMM) and Acetonitrile (ACN) expansions and multiple BSCL projects (HCN, NaCN, EDTA) are targeted for FY27 commissioning, forming the core of a ₹1,000 crore+ expansion cycle nearing completion.
Balance sheet and returns profile support the transition: standalone debt‑free status, consolidated debt of ₹133 crore with consolidated net worth of ₹2,152 crore, and a core chemical business ROCE of ~13%. Management emphasises funding from internal accruals and targeted structural margin expansion via backward integration and indigenous technologies.
Competitive advantages include deep vertical integration from feedstock to speciality chemicals, indigenous process technology with no royalty burden, and unique domestic positions (sole Indian producer of Electronic Grade DMC and domestic NMP producer), enabling Balaji Amines to capture higher value‑added segments across pharma, agro, EV batteries and industrial end markets.
Chemicals & Petrochemicals
Specialty Chemicals
5,923 Cr
High Risk
28.1
35.0
2.1
3.0
2,627.95
905.15
Sales CAGR
Profit CAGR
ROE
ROCE
Balaji Amines Ltd (BALAMINES) is currently trading at 1,824.00 per share. Stock prices fluctuate during market hours on NSE and BSE based on demand, company updates, and overall market conditions. Refer to the live price chart above for the most recent price movement.
Balaji Amines Limited is an integrated Indian speciality chemicals and amines manufacturer with multi‑location production in Maharashtra and Telangana, a 55% subsidiary Balaji Speciality Chemicals (BSCL), and a non‑core hospitality asset (Balaji Sarovar Premiere). The company produces core amines, derivatives, solvents and speciality chemistries and exports to over 50 countries while pursuing import substitution for regulated markets. Q1 FY27 consolidated results showed robust operational improvement: revenue from operations at ₹456 crore (up ~25.7% YoY), EBITDA ₹121 crore (26% margin, up from 17% YoY) and PAT ₹78 crore (110% YoY). Margin expansion was a key feature, driven by higher utilisation, product mix improvements and lower relative other expenses during the quarter. The company has advanced strategic capex: India’s first commercial 100,000 TPA Dimethyl Ether (DME) plant was commissioned in Q1 FY27, while N‑Methyl Morpholine (NMM) and Acetonitrile (ACN) expansions and multiple BSCL projects (HCN, NaCN, EDTA) are targeted for FY27 commissioning, forming the core of a ₹1,000 crore+ expansion cycle nearing completion. Balance sheet and returns profile support the transition: standalone debt‑free status, consolidated debt of ₹133 crore with consolidated net worth of ₹2,152 crore, and a core chemical business ROCE of ~13%. Management emphasises funding from internal accruals and targeted structural margin expansion via backward integration and indigenous technologies. Competitive advantages include deep vertical integration from feedstock to speciality chemicals, indigenous process technology with no royalty burden, and unique domestic positions (sole Indian producer of Electronic Grade DMC and domestic NMP producer), enabling Balaji Amines to capture higher value‑added segments across pharma, agro, EV batteries and industrial end markets.
Over the past 52 weeks, Balaji Amines Ltd has traded between a low of ₹905.15 and a high of ₹2,627.95. The 52-week high and low indicate the stock’s price range over the last year and help investors understand its volatility and recent trading levels.
Balaji Amines Ltd has a market capitalization of approximately 5,923.39. Market capitalization represents the total value of a company’s outstanding shares and helps investors understand its size, stability, and relative risk compared to other listed companies.
Balaji Amines Ltd’s investment profile depends on its business fundamentals, valuation, and long-term outlook. The stock currently trades at a PE ratio of 28.11 and operates in the its sector sector. Investors typically assess financial performance, growth prospects, and individual risk tolerance before making investment decisions.
Based on its market capitalization of 5,923.39 Cr, Balaji Amines Ltd is classified as a Small Cap stock. Large-cap stocks are generally more stable, while mid-cap and small-cap stocks tend to offer higher growth potential along with higher price volatility.
Balaji Amines Ltd operates in the its sector sector. Sector classification matters because companies in the same sector are often affected by similar economic conditions, regulatory changes, and competitive dynamics, which can influence overall stock performance.
The Price-to-Earnings (PE) ratio of Balaji Amines Ltd is 28.11. The PE ratio compares a company’s share price to its earnings and is commonly used to assess valuation. Comparing the PE ratio with sector peers and historical levels provides better context.
Revenue from operations was ₹455.92 crore in Q1 FY27, up 27.23% year-on-year from ₹358.34 crore.
The quarterly table shows consolidated total revenue of Rs 358.34 crore and net income (PAT) of Rs 38.00 crore for Q1 FY26.
Consolidated total revenue was reported at INR 403 crore (up 12% YoY). PAT was stated at INR 65 crore, while a filing-based snapshot reported PAT at INR 63.21 crore.
The stock surged after the company reported strong year-on-year growth across revenue, operating profit, and net profit for Q4 FY26 (quarter ended March 2026).
| Symbol | Watchlist | Price | Market Cap | P/E | P/B | Div Yield (%) | ROE (%) | ROCE (%) | ROA (%) |
711.55 | 7,563 Cr | 32.47 | 4.78 | 0.84 | 14.50 | 19.52 | 13.06 | ||
2176.90 | 6,540 Cr | 183.91 | 4.15 | 0.08 | 3.52 | 5.24 | 1.23 | ||
1828.15 | 5,923 Cr | 28.11 | 3.00 | 0.60 | 8.46 | 11.24 | 7.68 | ||
479.65 | 5,922 Cr | 61.93 | 3.06 | 0.52 | 5.52 | 7.20 | 3.59 | ||
49.19 | 5,728 Cr | 38.65 | 6.49 | 0.91 | 12.32 | 17.29 | 12.78 | ||
5738.10 | 4,325 Cr | 42.59 | 4.17 | 0.44 | 8.43 | 12.26 | 7.42 | ||
713.05 | 4,220 Cr | 96.75 | 9.43 | 0.16 | 0.00 | 0.00 | — | ||
| Median: 7 Co. | — | 713.05 | 5,922 Cr | 42.59 | 4.17 | 0.52 | 8.43 | 11.24 | 7.55 |
